Clinical applications of methadone

McQuay H : Opioids in pain management. Lancet. 1999; 353: 2229-2232.

Mercandante S : Costs are a further barrier to cancer pain management. Journal of Pain and Symptom Management. 1999; 18(1): 3-4.

Salzman RT , Roberts MS , Wild J , et al. : Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? Journal of Pain and Symptom Management. 1999; 18(4): 271-279.

Dickerson ED : 20 essential drugs in palliative care. European Journal of Palliative Care. 1999; 6(4): 130-135.

Kaye P : A to Z of Hospice and Palliative Medicine. Northamptom, UK: EPL Publications, 1994. 13.

Twycross R : Symptom Management in Advanced Cancer. 2nd Ed. Oxford, UK: Radcliffe Medical Press, 1997: 36.

Ventafridda V , Ripamonti C , Bianchi M , et al. : A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. Journal of Pain and Symptom Management. 1986; 1: 203-207.

Portenoy RK : 3 Step Analgesic Ladder for Management of Cancer Pain. New York: MacMahon Group, 1995: 13.

Stein C , Hassan AH , Lehrberger K , et al. : Local analgesic effect of endogenous opioid peptides. Lancet. 1993; 342: 321-324.

Woolf CJ , Thompson SW : The induction and maintenance of central sensitization is dependent on N-methyl-D-asperate acid receptor activation: Implications for the treatment of post-injury hypersensitivity states. Pain. 1991; 44: 293-299.

Portenoy RK : Pain in Oncologic and AIDS Patients. Newtown, PA: Handbooks in Health Care, 1997: 71.

Ebert B , Thorkildsen C , Andersen S , et al. : Opioid analgesics as noncompetitive N-methyl D-aspartate (NMDA) antagonists. Biochemical Pharmacology. 1998; 56(5): 553-559.

Purdue Pharma LP , Purdue Frederick Company : 1998 Pain Management Prescribing Guide. Norwalk, CT: Purdue Pharma LP, Purdue Frederick Company, 1998: 38.

Robinson AE , Williams FM : The distribution of methadone in man. Journal of Pharmacy and Pharmacology. 1971; 23: 353-358.

Eap CB , Cuendet C , Baumann P : Binding of D-methadone, L-methadone and DL-methadone to proteins in plasma of healthy volunteers: Role of variants of X1-acid glycoprotein. Clinical Pharmacology and Therapeutics. 1990; 47: 338-346.

Sawe J : High-dose morphine and methadone in cancer patients: Clinical pharmacokinetic consideration of oral treatment. Clinical Pharmacology. 1986; 11: 87-106.

Nilsson MI , Meresaar U , Anggard E : Clinical pharmacokinetics of methadone. Acta Anaesthesiologica Scandinavica. 1982; 74 (suppl): 66-69.

Kreek MJ , Schecter AJ , Gutjahr CL , Hecht M : Methadone use in patients with chronic renal disease. Drug Alcohol Dependence. 1980; 5: 197-205.

Novick DM , Kreek MJ , Fanizza AM , et al. : Methadone disposition in patients with chronic liver disease. Clinical Pharmacology and Therapeutics. 1981; 30: 353-362.

Beaver WT , Wallenstein SL , Houde RW , Rogers A : A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly and of orally and parenterally administered methadone. Clinical Pharmacology and Therapeutics. 1967; 8: 415-426.

Twycross R : Pain Relief in Advanced Cancer. Edinburgh: Churchill Livingstone, 1995:291.

Fainsinger R , Schoeller T , Bruera E : Methadone in the management of cancer pain: A review. Pain. 1993; 52: 137-147.

Inturrisi CE , Verebely K : The levels of methadone in the plasma in methadone maintenance. Clinical Pharmacology and Therapeutics. 1972; 13: 633-637.

Twycross R: op. cit.

Cadd EE , Shank RP , Schupsky JJ , Raffa RB : Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: Structural determinants and role in antinoception. Journal of Pharmacology and Experimental Therapeutics. 1995; 274(3): 1263-1270.

Dray A : Delta opioid receptors in pain: Function and therapy. Abstracts, 9th World Congress on Pain. Seattle: IASP Press, 1999: 113.

Makin MK , O’Donnell V , Skinner JM , Ellershaw JE : Methadone in the management of cancer related neuropathic pain: Report of five cases. Pain Clinic. 1998; 4: 275-279.

Eide PK : Clinical trails of NMDA receptor antagonists as analgesics. Abstracts, 9th World Congress on Pain. Seattle: IASP Press, 1999: 3.

Yaster M , Deshpande JK , Maxwell LG : The pharmacologic management of pain in children. Comprehensive Therapy. 1989; 15(10): 14-16.

O’Rourke MA , Shaiabi A , Webb S : Methadone for treatment of cancer pain. Journal of the American Medical Association. 1996; 275(7): 519.

Cherny NI , Portenoy RK : The management of cancer pain. Cancer Journal for Clinicians. 1994; 44: 262-303.

Twycross R : Introducing Palliative Care. 3rd Ed. Oxford, UK: Radcliffe Medical Press, 1999: 86.

Ripamonti C , Groff L , Brunelli C , et al. : Switching from morphine to oral methadone in treating cancer pain: What is the equal-analgesic dose ratio? Journal of Clinical Oncology. 1998; 16(10): 3216-3221.

Payne R : Pharmacologic management of pain. In Berger A , Portenoy RK , Weissman DE (eds.): Principles and Practice of Supportive Oncology. Philadelphia: Lippincott-Raven, 1998: 61-75.

Ripamonti C , Zecca E , Bruera E : An update of the clinical use of methadone for cancer pain. Pain. 1997; 70: 109-115.

Mercandante S , Sapio M , Serretta R , Caligara M : Patient-controlled analgesia with oral methadone in cancer pain: Preliminary report. Annals of Oncology. 1996; 7: 613-617.

DeConno F , Graff L , Brunelli C , et al. : Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. Journal of Clinical Oncology. 1996; 14(10): 2836-2842.

Shir Y , Shenkman Z , Shavelson V , et al. Oral methadone for the treatment of severe pain in hospitalized children: A report of five cases. Clinical Journal of Pain. 1998; 14(4): 350-353.

Joint Formulary Committee : British National Formulary. London: September 1996.

Gannon C : The use of methadone in the care of the dying. European Journal of Palliative Care. 1997; 4: 152-158.

Taube AW : The Use of Methadone in Cancer Pain Management: The Edmonton Experience. Edmonton, AB: Division of Palliative Medicine, Department of Oncology, University of Alberta, 1998.

Mancini I , Hanson J , Bruera E : Opioid type and other clinical predictors of laxative dose in advanced cancer patients: A retrospective study. Program Talk Summaries and Abstracts, 11th MASCC International Symposium, Supportive Care in Cancer. Nice, France: February 18-20, 1999: P-75.

Twycross R , Wilcock A , Thorp S : Palliative Care Formulary. Oxford, UK: Radcliffe Medical Press, 1998: 108.

Foley K : Methadone in cancer pain management: Individualize dose and titrate to effect. Journal of Clinical Oncology. 1998; 16(10): 3213-3215.

Makin MK , O’Donnell V , Skinner JM , Ellershaw JE : Methadone in the management of cancer related neuropathic pain: Report of five cases. The Pain Clinic. 1998; 10(4): 275-279.

Gannon C: op. cit.

Gardner-Nix JS : Oral methadone for managing chronic nonmalignant pain. Journal of Pain and Symptom Management. 1996; 11(5): 321-328.

Lipman AG : Clinically relevant differences among the opioid analgesics. American Journal of Hospital Pharmacy. 1990; 47(8): 7-13.

Pappagallo M , Heinberg LJ : Ethical issues in the management of chronic nonmalignant pain. Seminars in Neurology. 1997; 17(3): 203-211.

World Health Organization . Cancer Pain Relief. Geneva: World Health Organization, 1990.

Ahmedzai S : New approaches to pain control in patients with cancer. European Journal of Cancer. 1997; 33(6): 8-14.

Crews JC , Sweeny NJ , Denson DD : Clinical efficacy of methadone in patients refractory to other α-opioid receptor agonist analgesics for management of terminal cancer pain. Cancer. 1993; 72: 2266-2272.

Mercandante S , Casuccio A , Agnello A , et al. : Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. Journal of Clinical Oncology. 1998; 16(11): 3656-3661.